|
1
|
American Cancer Society. Cancer Facts and
Figures. Atlanta, Ga: American Cancer Society; 2009
|
|
2
|
National Cancer Institute. SEER Incidence:
Thyroid Cancer. Bethesda, MD: 2004
|
|
3
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A National Cancer Data Base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995. Cancer.
83:2638–2648. 1998.PubMed/NCBI
|
|
4
|
Engelbach M, Gorges R, Forst T, et al:
Improved diagnostic methods in the follow-up of medullary thyroid
carcinoma by highly specific calcitonin measurements. J Clin
Endocrinol Metab. 85:18902000.
|
|
5
|
Safioleas M, Stamatakos M, Karampali E,
Rompoti N, Mouzopoulos G and Lygidakis N: Diagnosis and treatment
aspects of medullary thyroid carcinoma. Chirurgia. 101:121–126.
2006.
|
|
6
|
Bhattacharyya N: A population-based
analysis of survival factors in differentiated and medullary
thyroid carcinoma. Otolaryngol Head Neck Surg. 128:115–123. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Modigliani E, Vasen HM, Raue K, et al:
Pheochromocytoma in multiple endocrine neoplasia type 2: European
study. The Euromen Study Group. J Intern Med. 238:363–367. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roman S, Lin R and Sosa JA: Prognosis of
medullary thyroid carcinoma: demographic, clinical, and pathologic
predictors of survival in 1252 cases. Cancer. 107:2134–2142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bergholm U, Bergström R and Ekbom A:
Long-term follow-up of patients with medullary carcinoma of the
thyroid. Cancer. 79:132–138. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kebebew E, Ituarte PH, Siperstein AE, Duh
QY and Clark OH: Medullary thyroid carcinoma: clinical
characteristics, treatment, prognostic factors and a comparison of
staging systems. Cancer. 88:1139–1148. 2000. View Article : Google Scholar
|
|
11
|
Jaquet AJ: Ein fall von metastasierenden
amyloidtumoren (lymphosarcoma). Virchows Arch. 185:251–267. 1906.
View Article : Google Scholar
|
|
12
|
Rufini V, Castaldi P, Treglia G, et al:
Nuclear medicine procedures in the diagnosis and therapy of
medullary thyroid carcinoma. Biomed Pharmacother. 62:139–146. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fialkowski EA and Moley JF: Current
approaches to medullary thyroid carcinoma, sporadic and familial. J
Surg Oncol. 94:737–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeLellis RA: Pathology and genetics of
thyroid carcinoma. J Surg Oncol. 94:662–669. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matoso A, Zhou Z, Hayama R,
Flesken-Nikitin A and Nikitin AY: Cell lineage-specific
interactions between Men1 and Rb in neuroendocrine neoplasia.
Carcinogenesis. 29:620–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boikos SA and Stratakis CA: Molecular
mechanisms of medullary thyroid carcinoma: current approaches in
diagnosis and treatment. Histol Histopathol. 23:109–116.
2008.PubMed/NCBI
|
|
17
|
Evans DB, Burgess MA, Goepfert H and Gagel
RF: Medullary thyroid cancer. Current therapy in endocrinology and
metabolism. 6th edition. Bardin CW: Mosby-Year Book; St. Louis: pp.
127–132. 1997
|
|
18
|
Liu FH, Hsueh C, Chang HY, Liou MJ, Huang
BY and Lin JD: Sonography and fine-needle aspiration biopsy in the
diagnosis of benign versus malignant nodules in patients with
autoimmune thyroiditis. J Clin Ultrasound. 37:487–492. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sippel RS, Kunnimalaiyaan M and Chen H:
Current management of medullary thyroid cancer. Oncologist.
13:539–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clark JR, Fridman TR, Odell MJ, Brierley
J, Walfish PG and Freeman JL: Prognostic variables and calcitonin
in medullary thyroid cancer. Laryngoscope. 115:1445–1450. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toledo SP, Lourenço DM Jr, Santos MA,
Tavares MR, Toledo RA and Correia-Deur JE: Hypercalcitoninemia is
not pathognomonic of medullary thyroid carcinoma. Clinics.
64:699–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lundgren CI, Delbridg L, Learoyd D and
Robinson B: Surgical approach to medullary thyroid cancer. Arq Bras
Endocrinol Metabol. 51:818–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oskam IM, Hoebers F, Balm AJ, et al: Neck
management in medullary thyroid carcinoma. Eur J Surg Oncol.
34:71–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dralle H and Machens A: Surgical
approaches in thyroid cancer and lymph-node metastases. Best Pract
Res Clin Endocrinol Metab. 22:971–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Machens A, Schneyer U, Holzhausen HJ and
Dralle H: Prospects of remission in medullary thyroid carcinoma
according to basal calcitonin level. J Clin Endocr Metab.
90:2029–2034. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al-Rawi M and Wheeler MH: Medullary
thyroid carcinoma – update and present management controversies.
Ann R Coll Surg Engl. 88:433–438. 2006.
|
|
27
|
Ball DW: Medullary thyroid cancer:
therapeutic targets and molecular markers. Curr Opin Oncol.
19:18–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
You YN, Lakhani V, Wells SA Jr and Moley
JF: Medullary thyroid cancer. Surg Oncol Clin N Am. 15:639–660.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schlumberger M, Carlomagno F, Baudin E,
Bidart JM and Santoro M: New therapeutic approaches to treat
medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab.
4:22–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cohen MS, Hussain HB and Moley JF:
Inhibition of medullary thyroid carcinoma cell proliferation and
RET phosphorylation by tyrosine kinase inhibitors. Surgery.
132:960–966. 2002. View Article : Google Scholar : PubMed/NCBI
|
